yingweiwo
  1. Home
  2. Products
  3. Signaling Pathways
  4. Angiogenesis
  5. BTK

BTK

BTK

BTK related products

Structure Cat No. Product Name CAS No. Product Description
(E/Z)-Rilzabrutinib V121811 (E/Z)-Rilzabrutinib 1575591-66-0 (E/Z)-Rilzabrutinib is the cis-trans isomer of Rilzabrutinib.
(R)-NX-2127 V87995 (R)-NX-2127 3024312-52-2 (R)-NX-2127 (compound 28) is an orally active Bruton's tyrosine kinase (Btk) degrader.
(Rac)-Ibrutinib alkyne V119798 (Rac)-Ibrutinib alkyne 936563-91-6 (Rac)-ibrutinib alkyne (compound 8) is a Btk inhibitor with an IC50 of 0.72 nM.
(Z)-LFM-A13 V0647 (Z)-LFM-A13 244240-24-2 (Z)-LFM-A13 (LFM-A1-3) is a novel, potent and specific Brutons tyrosine kinase (BTK) inhibitor with potential anticancer activity.
Btk substrate peptide V99657 Btk substrate peptide The Btk substrate peptide is a peptide substrate corresponding to residues 217-229 of human Bruton's tyrosine kinase (Btk), of which the tyrosine at residue 223 is the major autophosphorylation site of Btk.
BTK V416L Recombinant Human Active Protein Kinase V118856 BTK V416L Recombinant Human Active Protein Kinase Bruton's tyrosine kinase (BTK) plays a key role in the B cell antigen receptor (BCR) signaling pathway.
BTK-IN-43 V130719 BTK-IN-43 3081685-04-0 BTK-IN-43 is a BTK inhibitor with an IC50 value of 21.6 nM.
BTK/IKZF1/3 ligand 1 V116186 BTK/IKZF1/3 ligand 1 1791402-90-8 BTK/IKZF1/3 ligand 1 is a BTK/IKZF1/3 PROTAC ligand.
CFON-026 V131432 CFON-026 2941611-57-8 CFON-026 is a selective, orally effective non-covalent BTK inhibitor with an IC50 value of 0.27 nM.
CGI1746 V0646 CGI1746 910232-84-7 CGI1746 (CGI-1746) is a reversible/non-covalent and highly selective small-molecule inhibitor of the Brutons tyrosine kinase-Btk with potential anti-inflammatory activity.
CNX-774 V0645 CNX-774 1202759-32-7 CNX-774 (CNX774) is an irreversible/covalent, orally bioavailable, and highly selective inhibitor of BTK (Brutons tyrosine kinase) with potential anticancer activity.
Nemtabrutinib (ARQ-531) V4775 Nemtabrutinib (ARQ-531) 2095393-15-8 Nemtabrutinib (ARQ531; ARQ-531; MK-1026) is a novel, potent, orally bioavailable, and reversible / non-covalent BTK (Brutons Tyrosine Kinase) inhibitor with potential antitumor activity.
ONO-4059系列物 V0649 ONO-4059 analogue 1351635-67-0 ONO-4059 analogue, an analogue of ONO-4059, is a novel, covalent, selective and orally bioavailable BTK inhibitor with potential anticancer and anti-inflammatory activity.
PROTAC BTK/IKZF1/3 Degrader-1 V116185 PROTAC BTK/IKZF1/3 Degrader-1 2416130-49-7 PROTAC BTK/IKZF1/3 Degrader-1 is a selective, orally effective BCL6 and IKZF1/3 PROTAC degrader.
QL47B TFA V87991 QL47B TFA QL47B TFA is a biotinylated analog of QL47 and is a potent BTK inhibitor with an IC50 of 1.3 μM.
RN486 V0648 RN486 1242156-23-5 RN486 (RN-486) is a novel, potent, reversible and selective BTK (Brutons tyrosine kinase) inhibitorwith potential anti-inflammatory activity.
SRX3305 V145263 SRX3305 2409965-28-0 SRX3305 is a BTK/PI3K/BRD4 inhibitor with IC50 values of 6.5 nM, 15 nM, and 4 nM for BTK, PI3Kα, and PI3Kδ, respectively.
TLT8 V146173 TLT8 TLT8 is a ByeTAC protein degrader that targets BTK.
TM471-1 V146174 TM471-1 2649008-95-5 TM471-1 is an orally effective covalent Bruton's tyrosine kinase (BTK) inhibitor with IC50 values of 1.3 nM (BTKWT), >40,000 nM (BTKC481S), 7.9 nM (TEC), and 12.4 nM (TXK).
依鲁替尼 V0643 Ibrutinib (PCI-32765) 936563-96-1 Ibrutinib(formerly PCI32765; trade name Imbruvica), an approved anticancer drug, is a covalent/irreversible and orally bioavailableBrutons tyrosine kinase (Btk) inhibitor with potential anti-cancer activity.
Contact Us
Tel: 1-708-310-1919 Fax: 1-708-557-7486 Email: [email protected] Frequently Asked Questions
Subscribe to our E-newsletter
Name
E-mail

Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved

linkedin facebook
Contact Us
Home Product Cart Member